- Home
- CFFI vs GALT Comparison
CFFI vs GALT Comparison
Compare CFFI & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CFFI | GALT |
|---|---|---|
| Founded | 1927 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 298.3M | 297.0M |
| IPO Year | 1996 | 2008 |
Fundamental Metrics
Financial Performance| Metric | CFFI | GALT |
|---|---|---|
| Price | $93.48 | $4.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.50 |
| AVG Volume (30 Days) | 66.2K | ★ 298.4K |
| Earning Date | 04-23-2026 | 05-15-2026 |
| Dividend Yield | ★ 2.53% | N/A |
| EPS Growth | ★ 37.94 | 36.84 |
| EPS | ★ 4.71 | N/A |
| Revenue | ★ $140,841,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.75 | ★ N/A |
| Revenue Growth | ★ 10.63 | N/A |
| 52 Week Low | $65.39 | $2.03 |
| 52 Week High | $97.07 | $7.13 |
Technical Indicators
Market Signals| Indicator | CFFI | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 58.38 | 55.88 |
| Support Level | $69.33 | $2.74 |
| Resistance Level | N/A | $4.35 |
| Average True Range (ATR) | 2.44 | 0.26 |
| MACD | -0.36 | -0.02 |
| Stochastic Oscillator | 51.89 | 45.80 |
Price Performance
Historical ComparisonAbout CFFI C&F Financial Corporation
C&F Financial Corp is an American bank holding company. The company through its subsidiaries offers banking and related financial services to both individuals and businesses. It operates in three business activities: Community Banking, Mortgage Banking, and Consumer Finance. It mainly provides a range of lending activities, which include residential mortgage loans, commercial real estate loans, non-prime automobile lending, land acquisition, and development loans, and consumer loans. The company generates maximum of its revenue from the Community Banking segment.
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.